TransMedics Group (NASDAQ:TMDX) Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of TransMedics Group (NASDAQ:TMDX) from a buy rating to a hold rating in a report published on Saturday.

A number of other brokerages have also commented on TMDX. Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Canaccord Genuity Group lifted their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Morgan Stanley boosted their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Finally, Needham & Company LLC lifted their price target on TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Trading Up 0.0%

Shares of TransMedics Group stock opened at $133.99 on Friday. The stock has a market capitalization of $4.58 billion, a PE ratio of 54.25 and a beta of 2.03. TransMedics Group has a 52 week low of $62.07 and a 52 week high of $156.00. The stock has a 50 day moving average price of $134.17 and a two-hundred day moving average price of $123.88. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69.

Insiders Place Their Bets

In other news, Director David Weill sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the transaction, the director owned 12,134 shares in the company, valued at $1,682,257.76. The trade was a 29.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Gerardo Hernandez sold 920 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the transaction, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. This represents a 5.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 8,920 shares of company stock valued at $1,257,310. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Marshall Wace LLP boosted its position in TransMedics Group by 258.7% during the second quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after purchasing an additional 394,340 shares during the period. Two Sigma Investments LP raised its position in shares of TransMedics Group by 54.2% in the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after purchasing an additional 223,409 shares during the period. Zevenbergen Capital Investments LLC lifted its stake in shares of TransMedics Group by 112.7% during the 3rd quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock valued at $29,006,000 after buying an additional 136,995 shares in the last quarter. Next Century Growth Investors LLC bought a new position in TransMedics Group in the 2nd quarter worth approximately $16,049,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in TransMedics Group by 11.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after buying an additional 113,817 shares during the period. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.